UK bioscience companies form Rare Disease Industry Group
The BIA is committed ensuring patient access to treatments for rare and very rare conditions, sometimes referred to as orphan and ultra-orphan medicines...
List view / Grid view
The BIA is committed ensuring patient access to treatments for rare and very rare conditions, sometimes referred to as orphan and ultra-orphan medicines...
14 December 2016 | By Niamh Louise Marriott, Digital Editor
Prostate cancer can become resistant to hormone therapy and continue to grow despite treatment. Jevtana (cabazitaxel) is the only remaining chemotherapy...
13 December 2016 | By Niamh Louise Marriott, Digital Editor
The European Medicines Agency (EMA) has accepted for review the marketing authorisation application for Sanofi and Regeneron’s Dupixent (dupilumab) for the treatment of adults with moderate-to-severe atopic dermatitis who are candidates for systemic therapy.
21 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Sanofi and Regeneron presented results of a Phase 3 study demonstrating the superiority of investigational sarilumab monotherapy versus adalimumab...
3 November 2016 | By Niamh Louise Marriott, Digital Content Producer
Olipudase alfa is an enzyme replacement therapy being studied as a treatment of non-neurological manifestations of acid sphingomyelinase deficiency (ASMD)...
25 May 2016 | By Victoria White, Digital Content Producer
Jevtana has been recommended in combination with other drugs as a treatment option for metastatic hormone-relapsed prostate cancer in England...
19 April 2016 | By Mandy Parrett, Editorial Assistant
Sanofi has announced plans to invest €300 million to expand its manufacturing and commercial capabilities at its site in Geel, Belgium.